Related Experiment Videos
Type II collagen serology: a guide to clinical responsiveness to oral tolerance?
Abstract:
A double-blind placebo-controlled randomized trial of oral collagen type II (CII) treatment in rheumatoid arthritis was completed in Berlin. Anti-CII antibody titres were measured before and after the treatment. They showed that: (1) the titre prior to treatment did not identify a responder subgroup, (2) the treatment reduced CII antibody titres, but only in those patients making a clinical response and (3) administration of 10 mg CII per day reduced the titre in these subsets more effectively than 1 mg per day. Although the data are limited, they suggest that a titre drop may be useful for identifying those patients who respond to this form of treatment and that the drop may be a valid parameter for detecting the impact of the treatment on the immune system.
Insights
Oral collagen type II (CII) treatment for rheumatoid arthritis reduced anti-CII antibody titres in patients who responded clinically. A higher dose (10 mg) was more effective than a lower dose (1 mg).
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation.
- Autoantibodies, such as anti-collagen type II (anti-CII) antibodies, play a role in RA pathogenesis.
- Oral collagen type II (CII) is being investigated as a potential immunomodulatory treatment for RA.
Purpose of the Study:
- To evaluate the efficacy of oral collagen type II (CII) in patients with rheumatoid arthritis (RA).
- To assess the impact of oral CII treatment on anti-CII antibody titres.
- To determine if anti-CII antibody titres can predict treatment response.
Main Methods:
- A double-blind, placebo-controlled, randomized trial was conducted.
- Patients with RA received either oral collagen type II (CII) or a placebo.
- Anti-CII antibody titres were measured before and after treatment.
Main Results:
- Pre-treatment anti-CII antibody titres did not identify patients likely to respond to treatment.
- Oral CII treatment reduced anti-CII antibody titres, but only in patients who showed a clinical response.
- A daily dose of 10 mg of oral CII was more effective in reducing titres than 1 mg per day in responding patients.
Conclusions:
- A decrease in anti-CII antibody titres may indicate a positive response to oral collagen type II (CII) treatment in RA patients.
- Monitoring anti-CII antibody titre reduction could serve as a biomarker for treatment efficacy and immune system impact.
- Further research with larger sample sizes is warranted to confirm these findings.